WO2004065938A3 - Human osteoporosis gene - Google Patents

Human osteoporosis gene Download PDF

Info

Publication number
WO2004065938A3
WO2004065938A3 PCT/US2004/000990 US2004000990W WO2004065938A3 WO 2004065938 A3 WO2004065938 A3 WO 2004065938A3 US 2004000990 W US2004000990 W US 2004000990W WO 2004065938 A3 WO2004065938 A3 WO 2004065938A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
gene
human osteoporosis
human
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/000990
Other languages
French (fr)
Other versions
WO2004065938A2 (en
Inventor
Unnur Styrkarsdottir
Vala Drofn Johannsdottir
Jeffrey R Gulcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/661,887 external-priority patent/US6630304B1/en
Priority claimed from US10/346,723 external-priority patent/US20030176344A1/en
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Priority to EP04702489A priority Critical patent/EP1585837A2/en
Priority to CA002512239A priority patent/CA2512239A1/en
Priority to JP2006500965A priority patent/JP2006515992A/en
Publication of WO2004065938A2 publication Critical patent/WO2004065938A2/en
Publication of WO2004065938A3 publication Critical patent/WO2004065938A3/en
Anticipated expiration legal-status Critical
Priority to US11/185,033 priority patent/US20060057612A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A role of the human BMP2 nucleic acid in osteoporosis is disclosed. Methods for diagnosis, prediction of clinical course and treatment for osteoporosis or a susceptibility to osteoporosis using polymorphisms in the BMP2 nucleic acid, alone or in combination with other assays, are also disclosed.
PCT/US2004/000990 2000-09-14 2004-01-15 Human osteoporosis gene Ceased WO2004065938A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04702489A EP1585837A2 (en) 2003-01-16 2004-01-15 Human osteoporosis gene
CA002512239A CA2512239A1 (en) 2003-01-16 2004-01-15 Human osteoporosis gene
JP2006500965A JP2006515992A (en) 2003-01-16 2004-01-15 Human osteoporosis gene
US11/185,033 US20060057612A1 (en) 2000-09-14 2005-07-18 Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/661,887 US6630304B1 (en) 2000-09-14 2000-09-14 Human osteoporosis gene
PCT/IB2001/001667 WO2002022871A2 (en) 2000-09-14 2001-09-12 Polymorphic bone morphogenetic protein 2
US09/952,360 US20020072066A1 (en) 2000-09-14 2001-09-13 Human osteoporosis gene
US10/346,723 2003-01-16
US10/346,723 US20030176344A1 (en) 2000-09-14 2003-01-16 Human osteoporosis gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/185,033 Continuation-In-Part US20060057612A1 (en) 2000-09-14 2005-07-18 Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association

Publications (2)

Publication Number Publication Date
WO2004065938A2 WO2004065938A2 (en) 2004-08-05
WO2004065938A3 true WO2004065938A3 (en) 2004-10-28

Family

ID=56290520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000990 Ceased WO2004065938A2 (en) 2000-09-14 2004-01-15 Human osteoporosis gene

Country Status (1)

Country Link
WO (1) WO2004065938A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585838A2 (en) * 2003-01-16 2005-10-19 Decode Genetics EHF. Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association
WO2010073266A1 (en) * 2008-12-23 2010-07-01 Decode Genetics Ehf Sequence variants predictive of risk of kidney stones and bone mineral density

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022871A2 (en) * 2000-09-14 2002-03-21 Decode Genetics Ehf Polymorphic bone morphogenetic protein 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022871A2 (en) * 2000-09-14 2002-03-21 Decode Genetics Ehf Polymorphic bone morphogenetic protein 2

Also Published As

Publication number Publication date
WO2004065938A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004028341A3 (en) Susceptibility gene for human stroke; methods of treatment
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
AU3997300A (en) Gene sequence variations with utility in determining the treatment of disease
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
AU2001296511A1 (en) Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
WO1998008974A3 (en) Catalytic nucleic acid and its medical use
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
WO2004055162A3 (en) Modulation of endothelial lipase expression
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO1999054460A3 (en) Human nucleic acid sequences of normal bladder tissue
WO2003093429A3 (en) Nucleic acid reactions using labels with different redox potentials
WO2004048522A3 (en) Modulation of huntingtin interacting protein 2 expression
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
AU3717600A (en) Methods and reagents for decreasing clinical reaction to allergy
AU2002306850A1 (en) Methods and reagents for decreasing clinical reaction to allergy
WO2004043394A3 (en) Modulation of huntingtin interacting protein 1 expression
WO2004052309A3 (en) Modulation of stat 6 expression
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
WO2003064471A3 (en) Gene for peripheral arterial occlusive disease
WO2003062469A3 (en) Gene matn3 or matrilin-3 linked to osteoarthritis treatment
WO2004047741A3 (en) Modulation of iap-like expression
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2004053083A3 (en) Modulation of fetoprotein transcription factor expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2512239

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006500965

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11185033

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004702489

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004702489

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11185033

Country of ref document: US